The value of the private health care segment in Poland increased by about 4% year-on-year in 2010, to 28.8 billion zlotys ($10,38 billion), and is expected to be worth 34.4 billion zlotys ($12.39 billion) in 2013, according to the latest report published by the Polish research and consulting company PMR.
This figure includes payments for medicines and medical equipment, rehabilitation services, diagnostic tests and visits to doctors paid out of patients’ pockets, informal payments, subscriptions offered by medical companies, private health insurance sold by insurance companies and other charges covered directly by patients.
Market to grow 6% on average
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze